Yttrium-90 radioembolization is an increasingly utilized treatment for both primary and metastatic malignancies in the liver, according to Snmjournals. Interventional radiologists and nuclear medicine physicians rely on an understanding of biophysical properties, dosing concerns, and imaging appearance to provide this therapy. The procedure has proven efficacious and safe, although the possibility of complications does exist.
Overview of Yttrium-90 Radioembolization in Liver Malignancies
The intraarterial injection of the radioactive isotope Yttrium-90 has been discussed in the medical literature since 1965. Early attempts that year applied the isotope to treat primary liver and pancreatic cancers, yielding positive results alongside limited complications. As medical technology has advanced, the administration of Yttrium-90 has improved and become more widespread, establishing it as an effective tool in oncology.
Biophysical Properties and Delivery Advantages
Yttrium-90 functions as a beta-radiation emitter with a mean decay energy of 0.94 MeV. When delivered precisely to the tumor site, it causes cellular breakdown and tumor necrosis. The isotope features a half-life of approximately 64 hours and a tissue penetration of roughly 1 centimeter, which limits radiation exposure to the surrounding healthy liver parenchyma.
Intraarterial injection of these radiation particles offers several key advantages over systemic radiation. By placing the highest possible dose of radiation directly adjacent to the targeted tumor, the procedure spares normal liver tissue. Furthermore, the restricted tissue penetration makes intraarterial injection safer for medical personnel and the patient’s family.
Clinical Indications and Therapeutic Applications
Since its initial description, intraarterial Yttrium-90 therapy has been extensively studied for primary liver tumors. Hepatocellular carcinoma was historically difficult to treat because systemic chemotherapy demonstrated poor response rates and external-beam radiation caused significant damage to radiosensitive liver parenchyma. Later studies showed that outcomes for Yttrium-90 radioembolization in localized disease are similar to or better than other locoregional therapies, such as transarterial chemoembolization or ablation.
Additional studies on patient cohorts, such as a multi-center retrospective study reviewed by the Nature research publication, have analyzed hepatocellular carcinoma patients treated with radioembolization across various specialized medical sites. Depending on the institution, patients have received treatments utilizing either glass or resin microspheres, with volumetric evaluations performed via computed tomography or magnetic resonance imaging scans to monitor liver changes post-procedure.
Intrahepatic cholangiocarcinoma represents the second most common primary liver malignancy. While unresectable cases carry a poor prognosis, combination chemotherapy has improved overall survival but often brings systemic toxicity. Because intrahepatic cholangiocarcinoma is radiosensitive, palliative treatment with Yttrium-90 radioembolization has successfully demonstrated improved median survival with limited side effects.
Metastatic Liver Cancers and Palliative Care
Colorectal cancer stands as one of the most common malignancies worldwide, with the liver serving as the primary site for metastasis due to portal venous drainage. Untreated patients with liver metastases face a median survival of 6 to 9 months, while those with unresectable disease receiving chemotherapy achieve a median survival of 18 to 23 months. Because the hepatic site of disease drives the clinical outcome in the majority of patients, numerous liver-directed therapies have been developed to extend survival.
Similarly, neuroendocrine tumors commonly metastasize to the liver through portal venous drainage. While intraarterial embolization without radiation historically served as successful palliative therapy for unresectable disease, the technique was subsequently amplified by the introduction of Yttrium-90 microspheres given the radiosensitive nature of these tumors. However, for the specific treatment of neuroendocrine tumors, the Food and Drug Administration approved the radiopharmaceutical Lutathera, which may supplant Yttrium-90 radioembolization for this particular indication.
Keep reading